Immunotargeting with CD154 (CD40 Ligand) Enhances DNA Vaccine Responses in Ducks
- 1 August 2006
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 13 (8) , 958-965
- https://doi.org/10.1128/cvi.00080-06
Abstract
Engagement of CD154 on activated T cells with CD40 on antigen-presenting cells (APCs) potentiates adaptive immune responses in mammals. Soluble multimeric forms of CD154 have been used as an adjuvant or in immunotargeting strategies to enhance vaccine responses. The objective of our study was to examine the ability of duck CD154 (DuCD154) to enhance DNA vaccine responses in the duck hepatitis B model. Constructs were generated to express the functional domain of DuCD154 (tCD154), truncated duck hepatitis B virus (DHBV) core antigen (tcore) and chimera of tcore fused to tCD154 (tcore-tCD154). Expression in LMH cells demonstrated that all proteins were secreted and that tCD154 and tcore-tCD154 formed multimers. Ducks immunized with the plasmid ptcore-tCD154 developed accelerated and enhanced core-specific antibody responses compared to ducks immunized with ptcore or ptcore plus ptCD154. Antibody responses were better sustained in both ptcore-tCD154- and ptcore plus ptCD154-immunized ducks. Core-specific proliferative responses of duck peripheral blood mononuclear cells were enhanced in ducks immunized with ptcore-tCD154 or ptcore alone. This study suggests that the role of CD154 in the regulation of adaptive immune responses had already evolved before the divergence of birds and mammals. Thus, targeting of antigens to APCs with CD154 is an effective strategy to enhance DNA vaccine responses not only in mammalian species but also in avian species.Keywords
This publication has 54 references indexed in Scilit:
- Identification and characterization of functional CD154 (CD40 ligand) in the Pekin duckDevelopmental & Comparative Immunology, 2007
- Current Treatment of Chronic Hepatitis B: Benefits and LimitationsSeminars in Liver Disease, 2005
- Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriersHepatology, 2004
- Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligandInternational Journal of Cancer, 2003
- Progress in DNA vaccine for prophylaxis and therapy of hepatitis BVaccine, 2003
- Efficacy and limitations of a specific immunotherapy in chronic hepatitis BJournal of Hepatology, 2001
- Modulation of Cellular Responses by Plasmid CD40L: CD40L Plasmid Vectors Enhance Antigen-Specific Helper T Cell Type 1 CD4+T Cell-Mediated Protective Immunity against Herpes Simplex Virus Type 2in VivoHuman Gene Therapy, 2001
- A central role of CD40 ligand in the regulation of CD4+ T-cell responsesImmunology Today, 1996
- A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activationEuropean Journal of Immunology, 1995
- Structural characteristics of CD40 ligand that determine biological functionSeminars in Immunology, 1994